

7. Bader HL, Hsu T. Systemic VHL gene functions and the VHL disease. *FEBS Lett.* 2012; 586(11): 1562–1569.
8. Richard S, Graff J, Lindau J, Resche F. Von Hippel-Lindau disease. *Lancet.* 2004; 363(9416): 1231–1234.
9. Üрге T, Hora M, Toufarová P, et al. Renální karcinom u nemocných s morbus von Hippel-Lindau. *Ces Urol* 2007; 11(2): 93–97.
10. Nielsen SM, Rhodes L, Blanco I, et al. Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. *J Clin Oncol.* 2016; 34(18): 2172–2181.
11. Lattouf JB, Pautler SE, Reaume MN, et al. Structured assessment and followup for patients with hereditary kidney tumour syndromes. *Can Urol Assoc J.* 2016; 10(7–8): E214–E22.
12. Maddock IR, Moran A, Maher ER, et al. A genetic register for von Hippel-Lindau disease. *J Med Genet* 1996; 33(2): 120–127.
13. Ong KR, Woodward ER, Killick P, et al. Genotype-phenotype correlations in von Hippel-Lindau disease. *Hum Mutat.* 2007; 28(2): 143–149.
14. Deml KF, Schildhaus HU, Compérat E, et al. Clear cell papillary renal cell carcinoma and renal angio-myoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma. *Am J Surg Pathol.* 2015; 39(7): 889–901.
15. Maher ER, Neumann HP, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. *Eur J Hum Genet.* 2011; 19(6): 617–623.
16. Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. *J Urol.* 1999; 161(5): 1475–1479.
17. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. *J Urol.* 2004; 172(1): 63–65.
18. Guo J, Tretiakova MS, Troxell ML, et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. *Am J Surg Pathol.* 2014; 38(11): 1457–1467.
19. Vrtel R, Filipová H, Vodicka R, et al. Tuberous sclerosis. *Klin Onkol.* 2009; 22(Suppl): S50–53.
20. Northrup H, Krueger DA, Group ITSCC. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol.* 2013; 49(4): 243–254.
21. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. *J Child Neurol.* 2004; 19(9): 643–649.
22. Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. *Nephron Exp Nephrol.* 2011; 118(1): e15–20.
23. Tello R, Blickman JG, Buonomo C, Herrin J. Meta analysis of the relationship between tuberous sclerosis complex and renal cell carcinoma. *Eur J Radiol.* 1998; 27(2): 131–138.
24. Moch H, Ohashi R, Gandhi JS, Amin MB. Morphological clues to the appropriate recognition of hereditary renal neoplasms. *Semin Diagn Pathol.* 2018; 35(3): 184–192.
25. Palsgrove DN, Li Y, Pratilas CA, et al. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum. *Am J Surg Pathol.* 2018; 42(9): 1166–1181.
26. Trpkov K, Hes O. New and emerging renal entities: a perspective post-WHO 2016 classification. *Histopathology* 2019; 74(1): 31–59.
27. Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity. *Am J Surg Pathol.* 2017; 41(10): 1299–308.
28. Carlo MI, Hakimi AA, Stewart GD, et al. Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. *Eur Urol.* 2019; 76(6): 754–764.
29. Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. *PLoS One.* 2011; 6(9): e23379.